Maviret Wins EU Approval to Treat Acute Hepatitis C, Moving the Front Line of Viral Clearance Earlier

The most difficult aspect of hepatitis C is often not just the virus itself, but the time it gains through silent infection and delayed diagnosis. If the virus can be cleared during the acute infection stage, patients do not have to wait until the disease becomes chronic before starting treatment, and public health efforts may also reduce the risk of later transmission and long-term liver damage.

AbbVie announced on June 23 that the European Commission has approved Maviret for the treatment of acute hepatitis C virus infection, with the indicated population including adults and children aged 3 and older. Maviret is a direct-acting antiviral composed of glecaprevir and pibrentasvir, and had previously been used in the EU for chronic hepatitis C; after this approval, its EU indication spans both acute and chronic infection.

Hepatitis C can be transmitted through blood exposure. Some infected people have mild symptoms during the acute phase or no obvious discomfort, causing them to miss early confirmation and intervention. In the past, clinical practice often focused treatment on chronic hepatitis C, but as highly effective oral antivirals have matured, treatment strategies have gradually shifted toward earlier intervention to prevent the disease course from being prolonged into chronic infection.

This approval is mainly supported by Phase 3 clinical data. According to data released by AbbVie, 96.2% of the intention-to-treat population achieved SVR12 after receiving Maviret treatment. SVR12 means the virus remains undetectable 12 weeks after the end of treatment, and is usually regarded as an important marker of successful hepatitis C treatment.

However, the publicly available information this time is still mainly based on the company announcement, with limited independent external data on the same event; therefore, details on the trial population composition and performance across different age groups or viral genotypes still require review of full regulatory documents or formally published data for a more precise assessment. For general readers, the 96.2% figure represents a strong efficacy signal, but does not mean every category of patient will have exactly the same result.

For the pediatric population, the inclusion of children aged 3 and older in the indication is a clinically meaningful part of this approval. Pediatric hepatitis C cases are relatively uncommon, but may occur due to vertical infection or other blood exposure; having a clearly approved treatment option for younger age groups helps physicians follow a clearer medication framework after diagnosis.

The real challenge may not be whether the drug exists, but whether patients can be found. Acute hepatitis C is often difficult to identify in real time, and screening, referral, access to medication, and reimbursement processes in each country will determine the extent to which this approval can be translated into public health outcomes. The EU regulatory decision opens a door to early treatment; next, clinical systems must enable patients to reach that door before the virus has left a long shadow.